# ë°°ê²½ ìžë£Œ: S1 ì„¸ê·  ë³‘ì›ì„±

**ì„¸ì…˜**: S1 - Bacterial Pathogenesis
**ì¼ì‹œ**: 2025ë…„ 10ì›” 26ì¼ (ì¼) 13:30-15:30
**ìž¥ì†Œ**: ìˆ˜ì›ì»¨ë²¤ì…˜ì„¼í„°
**ì¤‘ìš”ë„**: â­â­â­ (75/100ì ) - **ì„¸ê·  ë³‘ì›ì„± ì—°êµ¬ìž í•„ìˆ˜!**

---

## ðŸŽ¯ ì„¸ì…˜ ê°œìš”

ì´ ì„¸ì…˜ì€ **ì„¸ê·  ë³‘ì›ì„±ì˜ ìµœì‹  ë©”ì»¤ë‹ˆì¦˜**ì„ ë‹¤ë£¹ë‹ˆë‹¤. ë…ì†Œ ì‹œìŠ¤í…œ(MARTX), ì„¸ê·  ìƒì¡´ ì „ëžµ(VBNC), ë¶„ë¹„ ì‹œìŠ¤í…œ(T6SS), ì„¸ê·  ê°„ ê²½ìŸì´ë¼ëŠ” ë„¤ ê°€ì§€ í•µì‹¬ ì£¼ì œë¥¼ í†µí•´ ë³‘ì›ì„± ì„¸ê· ì´ ì–´ë–»ê²Œ í™˜ê²½ê³¼ ìˆ™ì£¼ì—ì„œ ìƒì¡´í•˜ê³  ê³µê²©í•˜ëŠ”ì§€ ì´í•´í•  ìˆ˜ ìžˆìŠµë‹ˆë‹¤.

### ì™œ ì´ ì„¸ì…˜ì´ ì¤‘ìš”í•œê°€?

- ðŸ§¬ **ë‹¤ì–‘í•œ ë³‘ì›ì„± ë©”ì»¤ë‹ˆì¦˜**: ë…ì†Œ, ë¶„ë¹„ ì‹œìŠ¤í…œ, ìƒì¡´ ì „ëžµì˜ í†µí•©ì  ì´í•´
- ðŸ”¬ **ìµœì‹  ì—°êµ¬ ë™í–¥**: Phase separation, VBNC state ë“± 2025ë…„ ìµœì‹  ë°œê²¬
- ðŸ¦  **Vibrio ì—°êµ¬ ì§‘ì¤‘**: V. vulnificus, V. cholerae ë³‘ì›ì„± ì‹¬ì¸µ ë¶„ì„
- ðŸ’¡ **ì„¸ê· í•™ ê¸°ì´ˆ ì—°êµ¬**: ì¼ë°˜ ì„¸ê· í•™ ì‹¤í—˜ì‹¤ì— ì§ì ‘ ì ìš© ê°€ëŠ¥í•œ ê°œë…ë“¤

### ëž© êµ¬ì„±ì›ë“¤ì—ê²Œ ìœ ìš©í•œ ì´ìœ 

**ì„¸ê·  ë³‘ì›ì„± ì—°êµ¬ìž**:
- MARTX ë…ì†Œ, T6SS ë¶„ë¹„ ì‹œìŠ¤í…œì˜ ìµœì‹  ë©”ì»¤ë‹ˆì¦˜
- ì„¸ê·  ê°„ ê²½ìŸê³¼ predationì˜ ìƒíƒœí•™ì  ì˜ë¯¸

**ë¯¸ìƒë¬¼í•™ ì¼ë°˜**:
- VBNC ìƒíƒœ: ë°°ì–‘ ë¶ˆê°€ëŠ¥ ì„¸ê· ì˜ ìƒì¡´ê³¼ ê²€ì¶œ ì „ëžµ
- Phase separation: ì„¸ê·  ì„¸í¬ ìƒë¬¼í•™ì˜ ìƒˆë¡œìš´ íŒ¨ëŸ¬ë‹¤ìž„

**ê°ì—¼ë³‘ ì—°êµ¬ìž**:
- Vibrio ê°ì—¼ ë©”ì»¤ë‹ˆì¦˜ê³¼ ë°©ì–´ ì „ëžµ
- í™˜ê²½ì—ì„œì˜ ë³‘ì›ì²´ persistence

---

## ðŸ“‹ ë°œí‘œë³„ ìƒì„¸ ë¶„ì„

### ðŸ”¹ ë°œí‘œ 1 (13:30-13:55)

**ì—°ì‚¬**: Byoung Sik Kim (ê¹€ë³‘ì‹)
**ì†Œì†**: Sogang University (ì„œê°•ëŒ€í•™êµ)
**ì œëª©**: *Vibrio vulnificus* MARTX toxin and N-glycan binding mechanism

#### ìµœê·¼ ì—°êµ¬ ë°°ê²½

Kim êµìˆ˜íŒ€ì€ **ë¹„ë¸Œë¦¬ì˜¤ íŒ¨í˜ˆì¦ ì›ì¸ê· ì¸ *Vibrio vulnificus*ì˜ ì£¼ìš” ë…ì†Œì¸ MARTX toxin**ì„ ì—°êµ¬í•˜ê³  ìžˆìŠµë‹ˆë‹¤.

**MARTX = Multifunctional-Autoprocessing Repeats-in-Toxin**

**í•µì‹¬ ì—°êµ¬ ì„±ê³¼**:
- **2020ë…„**: MARTX toxin-host ìƒí˜¸ìž‘ìš© dual-transcriptome ë¶„ì„ (mSphere)
- **2021ë…„**: ë‚®ì€ ë…ì„± MARTX variantê°€ ìˆ™ì£¼ reservoirsì—ì„œ persistence ì¦ê°€ì‹œí‚´ (JBC)
- **2015ë…„**: MARTX toxinì˜ effector domainê³¼ repeat regionì˜ distinct roles (mBio)

**ìµœì‹  ì—°êµ¬ (2025ë…„ ì˜ˆìƒ)**:
- **N-glycan ê²°í•© ë©”ì»¤ë‹ˆì¦˜**: MARTX toxinì´ ìˆ™ì£¼ ì„¸í¬ í‘œë©´ì˜ N-glycanì„ ì¸ì‹í•˜ëŠ” ìƒˆë¡œìš´ ë©”ì»¤ë‹ˆì¦˜ ë°œê²¬
- **Cell blebbing vs. effector translocation ë¶„ë¦¬**: ì„¸í¬ë§‰ ì†ìƒê³¼ effector ì „ë‹¬ì´ ë…ë¦½ì  ê³¼ì •ìž„ì„ ê·œëª…

#### ì˜ˆìƒ ë°œí‘œ ë‚´ìš©

**1. MARTX Toxinì˜ êµ¬ì¡°ì™€ ê¸°ëŠ¥**

**ë…ì†Œ êµ¬ì¡°**:
```
N-terminal repeats â†’ Effector 1 â†’ CPD â†’ Effector 2 â†’ ... â†’ C-terminal repeats
   (Pore forming)     (ë…ì„± ê¸°ëŠ¥)  (Protease)  (ë…ì„± ê¸°ëŠ¥)      (Pore forming)
```

**Components**:
- **Glycine-rich repeats (GRRs)**: N-ë§ë‹¨ê³¼ C-ë§ë‹¨ì— ìœ„ì¹˜, ì„¸í¬ë§‰ pore í˜•ì„±
- **Effector domains**: 3-5ê°œì˜ ë…ì„± effector (ë…ì†Œë§ˆë‹¤ ë‹¤ë¦„)
  - ACD (Actin Cross-linking Domain): ì•¡í‹´ ì¤‘í•© êµëž€
  - RID (Rho Inactivation Domain): Rho GTPase ë¶ˆí™œì„±í™”
  - ABH (Alpha-Beta Hydrolase): ì„¸í¬ ì‹ í˜¸ ë°©í•´
  - Makes catfish (MC): Apoptosis ìœ ë„
- **CPD (Cysteine Protease Domain)**: InsP6 í™œì„±í™”ë¡œ effector ì ˆë‹¨/ë°©ì¶œ

**2. MARTX Toxin ìž‘ë™ ë©”ì»¤ë‹ˆì¦˜**

**Step-by-step Process**:
```
1. ë…ì†Œ ê²°í•© (Receptor binding)
   â†“ (N-glycan ì¸ì‹?)
2. Pore í˜•ì„± (GRRsê°€ ì„¸í¬ë§‰ ì‚½ìž…)
   â†“ (1.6 nm pore)
3. Effector translocation
   â†“ (Unfolding í•„ìš”)
4. InsP6 influx
   â†“ (ì„¸í¬ì§ˆ InsP6ê°€ pore í†µê³¼)
5. CPD í™œì„±í™”
   â†“
6. Effector ì ˆë‹¨/ë°©ì¶œ
   â†“
7. ê°œë³„ effector ê¸°ëŠ¥ ë°œí˜„
   â†“
ì„¸í¬ ì‚¬ë©¸ (Necrosis, blebbing)
```

**3. N-glycan Binding Mechanism**

**ë°°ê²½**:
- 2024ë…„ Nature ë…¼ë¬¸: MARTX toxinì´ biantennary N-glycansë¥¼ receptorë¡œ ì‚¬ìš©
- ì„¸í¬ í‘œë©´ glycoproteinsì˜ N-glycanì´ ë…ì†Œ ê²°í•© ë¶€ìœ„

**ë©”ì»¤ë‹ˆì¦˜ ì˜ˆìƒ**:
- **Receptor domain**: MARTX toxin N-ë§ë‹¨ ë˜ëŠ” repeat regionì´ N-glycan ê²°í•©
- **Specificity**: Biantennary (2-branch) N-glycan ì„ í˜¸ì„±
- **Binding affinity**: Multivalent binding (ì—¬ëŸ¬ N-glycan ë™ì‹œ ê²°í•©)

**ìƒë¬¼í•™ì  ì˜ë¯¸**:
- N-glycansëŠ” ëŒ€ë¶€ë¶„ì˜ ì„¸í¬ í‘œë©´ glycoproteinsì— ì¡´ìž¬
- â†’ Broad host range ì„¤ëª… ê°€ëŠ¥
- â†’ ë°±ì‹ /ì¹˜ë£Œì œ íƒ€ê²Ÿ: N-glycan ê²°í•© ì°¨ë‹¨

**4. Cell Blebbing vs. Effector Translocation**

**Kim êµìˆ˜íŒ€ ë°œê²¬ (2015 mBio)**:
- **Cell blebbing**: Effector domains í•„ìš” (ACD, RID ë“±)
- **Cell lysis**: Repeat regionsë§Œìœ¼ë¡œë„ ê°€ëŠ¥ (pore í˜•ì„±)
- â†’ ë‘ ê³¼ì •ì´ ë…ë¦½ì !

**ì˜ë¯¸**:
```yaml
Pore formation (GRRs):
  - Cell lysis ìœ ë°œ
  - Effector ì—†ì´ë„ ì„¸í¬ íŒŒê´´ ê°€ëŠ¥

Effector translocation:
  - Specific cellular functions êµëž€
  - ACD â†’ Actin crosslinking â†’ Blebbing
  - RID â†’ Rho inactivation â†’ Cytoskeleton collapse
```

**5. V. vulnificus ë³‘ì›ì„±ê³¼ MARTX**

**ê°ì—¼ ê²½ë¡œ**:
- **ê²½êµ¬**: ë‚  í•´ì‚°ë¬¼ ì„­ì·¨ (êµ´, ì–´íŒ¨ë¥˜)
- **í”¼ë¶€**: ìƒì²˜ í†µí•´ í•´ìˆ˜ ë…¸ì¶œ

**ì¦ìƒ**:
- **ìœ„ìž¥ê´€ ê°ì—¼**: ì„¤ì‚¬, ë³µí†µ
- **íŒ¨í˜ˆì¦**: ì¹˜ì‚¬ìœ¨ 50% ì´ìƒ (ë©´ì—­ì €í•˜ í™˜ìž)
- **í”¼ë¶€ ê´´ì‚¬**: Necrotizing fasciitis

**MARTXì˜ ì—­í• **:
- ì´ˆê¸° ê°ì—¼: ìž¥ ìƒí”¼ ì„¸í¬ íŒŒê´´
- ì „ì‹  ê°ì—¼: í˜ˆê´€ ë‚´í”¼ ì„¸í¬ ì†ìƒ â†’ ì¶œí˜ˆ, shock
- ë©´ì—­ íšŒí”¼: Macrophage ì‚¬ë©¸

#### ì—°êµ¬ì™€ì˜ ì—°ê²°ì 

**ì¼ë°˜ ì„¸ê· í•™ ì‹¤í—˜ì‹¤ ê´€ì **:

**1. ë…ì†Œ ì—°êµ¬ ëª¨ë¸ ì‹œìŠ¤í…œ**:
- **MARTX as a model**: ë‹¤ê¸°ëŠ¥ ë…ì†Œì˜ ëŒ€í‘œì  ì˜ˆì‹œ
- **Effector delivery platform**: ë‹¤ë¥¸ ì„¸ê· ì˜ ë…ì†Œ ì „ë‹¬ ë©”ì»¤ë‹ˆì¦˜ ì´í•´
- **Structure-function relationship**: Domain ê¸°ë°˜ ë…ì†Œ ë¶„ì„ ë°©ë²•ë¡ 

**2. Glycan-Protein ìƒí˜¸ìž‘ìš© ì—°êµ¬**:
- **Receptor identification**: N-glycanì´ ì„¸ê·  ë…ì†Œ receptorë¡œ ê¸°ëŠ¥
- **Glycobiology**: ì„¸ê· -ìˆ™ì£¼ ìƒí˜¸ìž‘ìš©ì—ì„œ glycanì˜ ì—­í• 
- **ì‘ìš©**: Glycan-based inhibitor ê°œë°œ ì „ëžµ

**3. ì„¸ê·  ë¶„ë¹„/ì „ë‹¬ ì‹œìŠ¤í…œ**:
```yaml
MARTX vs. ë‹¤ë¥¸ ë¶„ë¹„ ì‹œìŠ¤í…œ ë¹„êµ:
  Type III Secretion:
    - Needle complex
    - Direct injection
    - ì—¬ëŸ¬ effector ìˆœì°¨ ì „ë‹¬

  MARTX:
    - Pore-forming toxin
    - Effectorê°€ toxinì— pre-loaded
    - InsP6ë¡œ CPD í™œì„±í™” â†’ ì¼ê´„ ë°©ì¶œ

  ê³µí†µì : Effector-based pathogenesis
```

**4. ì„¸ê·  ë…ì„± ì§„í™”**:
- **Effector domain diversity**: ë‹¤ë¥¸ Vibrio speciesì˜ MARTX ë¹„êµ
- **Horizontal gene transfer**: Effector cassette êµí™˜
- **Virulence trade-off**: ë…ì„± vs. persistence (2021 JBC ì—°êµ¬)

**5. ì‹¤í—˜ ê¸°ë²• ì‘ìš©**:
- **Dual-transcriptomics**: ìˆ™ì£¼-ë³‘ì›ì²´ ë™ì‹œ RNA-seq
- **Domain deletion mutants**: Effector ê¸°ëŠ¥ ê°œë³„ ë¶„ì„
- **Cell-based assays**: Blebbing, lysis, actin staining

#### í•„ìˆ˜ ë°°ê²½ ì§€ì‹

**1. Pore-Forming Toxins (PFTs)**

**ë¶„ë¥˜**:
| Type | Example | Mechanism |
|------|---------|-----------|
| **Î±-PFTs** | Î±-Hemolysin | Î±-helix insertion |
| **Î²-PFTs** | Perfringolysin O | Î²-barrel formation |
| **RTX toxins** | **MARTX**, CyaA | Glycine-rich repeats, CaÂ²âº-dependent |

**RTX (Repeat in ToXin) family**:
- **Glycine-rich nonapeptide repeats**: GGXGXDXUX (X = any amino acid)
- **CaÂ²âº binding**: Repeat regionsì´ CaÂ²âº ê²°í•© â†’ êµ¬ì¡° stabilization
- **Type I secretion**: ABC transporterë¡œ ë¶„ë¹„ (MARTXëŠ” ì˜ˆì™¸ì ìœ¼ë¡œ í¬ê¸°ê°€ í¼)

**2. Cysteine Protease Domain (CPD)**

**íŠ¹ì§•**:
- **Catalytic triad**: Cys-His-Asp (ë˜ëŠ” Glu)
- **InsP6 (Inositol hexaphosphate) activation**:
  - InsP6 = IP6, ì„¸í¬ì§ˆì— í’ë¶€ (10-100 Î¼M)
  - CPD í™œì„± ë¶€ìœ„ì— ê²°í•© â†’ í™œì„±í™”
  - â†’ ì„¸í¬ ë‚´ë¶€ì—ì„œë§Œ í™œì„±í™”! (ì„¸í¬ ë°–ì—ì„œëŠ” ë¶ˆí™œì„±)

**Autoprocessing**:
```
Holo-MARTX â†’ CPD activation by InsP6 â†’ Effector cleavage â†’ Free effectors
```

**3. MARTX Effector Domains**

**ëŒ€í‘œì  effectors**:
| Effector | Function | Target | Effect |
|----------|----------|--------|--------|
| **ACD** | Actin crosslinking | Actin monomers | Actin aggregation, blebbing |
| **RID** | Rho inactivation | RhoA, Rac1, Cdc42 | Cytoskeleton collapse |
| **ABH** | Hydrolase | Lipid signaling | Unknown |
| **Makes catfish** | Pro-apoptotic | Caspase? | Apoptosis |
| **VIP2-like** | ADP-ribosylation | Actin | Actin depolymerization |

**4. N-glycan Structure**

**N-glycosylation**:
- **Attachment**: Asn (N) residue in Asn-X-Ser/Thr motif
- **Core structure**: GlcNAc2-Man3
- **Branches**: High-mannose, Complex, Hybrid

**Biantennary N-glycan**:
```
        GlcNAc-Gal-Sia
       /
GlcNAc2-Man3
       \
        GlcNAc-Gal-Sia
```
- 2ê°œì˜ branches (antennae)
- ê°€ìž¥ í”í•œ complex N-glycan type
- ì„¸í¬ í‘œë©´ glycoproteinsì— í’ë¶€

**5. Cell Blebbing Mechanism**

**Blebbingì´ëž€?**:
- ì„¸í¬ë§‰ì´ í’ì„ ì²˜ëŸ¼ ë¶€í’€ì–´ ì˜¤ë¥´ëŠ” í˜„ìƒ
- Cytoskeleton-membrane detachment

**ë©”ì»¤ë‹ˆì¦˜**:
```
Normal: Actin cortex âŸ· Plasma membrane (ì—°ê²°)
  â†“ (MARTX ACD)
Actin crosslinking â†’ Cortex contraction
  â†“
Membrane-cortex detachment
  â†“
Hydrostatic pressure â†’ Membrane protrusion
  â†“
Bleb formation
```

**ìƒë¬¼í•™ì  ì˜ë¯¸**:
- Necrotic cell death ì§•í›„
- Membrane integrity ì†ì‹¤
- ì„¸í¬ ì‚¬ë©¸ ì „ ë‹¨ê³„

#### ì˜ˆìƒ ì§ˆë¬¸ & í† ë¡  í¬ì¸íŠ¸

**ë‹¹ì‹ ì´ ë¬¼ì–´ë³¼ ì§ˆë¬¸**:

1. "**N-glycan ê²°í•©ì˜ íŠ¹ì´ì„±**ì€ ì–´ëŠ ì •ë„ì¸ê°€ìš”? V. vulnificusê°€ íŠ¹ì • ì¡°ì§/ì„¸í¬ë¥¼ ì„ í˜¸í•˜ëŠ” ê²ƒê³¼ ì—°ê´€ì´ ìžˆë‚˜ìš”?"

2. "**ë‹¤ë¥¸ Vibrio speciesì˜ MARTX**ì™€ ë¹„êµí–ˆì„ ë•Œ, V. vulnificus MARTXì˜ ë…íŠ¹í•œ íŠ¹ì§•ì€ ë¬´ì—‡ì¸ê°€ìš”? Effector compositionì´ ë³‘ì›ì„±ì— ì–´ë–¤ ì˜í–¥ì„ ë¯¸ì¹˜ë‚˜ìš”?"

3. "**CPD knockout mutant**ëŠ” ì–´ë–¤ í‘œí˜„í˜•ì„ ë³´ì´ë‚˜ìš”? Effectorê°€ ë°©ì¶œë˜ì§€ ì•Šì•„ë„ pore í˜•ì„±ë§Œìœ¼ë¡œ ë…ì„±ì´ ìžˆë‚˜ìš”?"

4. "**In vivoì—ì„œ MARTX toxinì˜ ì£¼ìš” íƒ€ê²Ÿ ì„¸í¬**ëŠ”? ìž¥ ìƒí”¼, í˜ˆê´€ ë‚´í”¼, ë©´ì—­ ì„¸í¬ ì¤‘ ì–´ë””ê°€ ê°€ìž¥ ì¤‘ìš”í•œê°€ìš”?"

5. "**Anti-MARTX í•­ì²´ë‚˜ N-glycan mimics**ë¥¼ ì´ìš©í•œ ì¹˜ë£Œ ì „ëžµ ê°€ëŠ¥ì„±ì€?"

**í† ë¡  ì˜ˆìƒ**:
- **MARTX vs. Type III Secretion System**: Effector delivery íš¨ìœ¨ì„± ë¹„êµ
- **Virulence-persistence trade-off**: 2021 JBC ë…¼ë¬¸, ë…ì„± ì•½í•œ variantê°€ ì˜¤ížˆë ¤ ì˜¤ëž˜ ìƒì¡´
- **í™˜ê²½ì—ì„œì˜ MARTX ì—­í• **: í•´ì–‘ í™˜ê²½ì—ì„œ ë‹¤ë¥¸ ì„¸ê·  ê³µê²©? Amoeba ë°©ì–´?
- **MARTX ì§„í™”**: Effector cassetteì˜ horizontal gene transfer

**ë„¤íŠ¸ì›Œí‚¹**:
- ì¤‘ê°„ ìš°ì„ ìˆœìœ„ (ë…ì†Œ ì—°êµ¬ì— ê´€ì‹¬ ìžˆë‹¤ë©´ ë†’ìŒ)
- êµ­ë‚´ ì—°êµ¬ìž (ì„œê°•ëŒ€) â†’ ì ‘ê·¼ ìš©ì´
- Vibrio ì—°êµ¬, ë…ì†Œ ë©”ì»¤ë‹ˆì¦˜ ê´€ì‹¬ì‚¬ ê³µìœ 

---

### ðŸ”¹ ë°œí‘œ 2 (13:55-14:20)

**ì—°ì‚¬**: Zhenbo Xu (å¾æŒ¯æ³¢)
**ì†Œì†**: South China University of Technology
**ì œëª©**: VBNC (Viable But Non-Culturable) state in bacteria

#### ìµœê·¼ ì—°êµ¬ ë°°ê²½

Xu êµìˆ˜ëŠ” **VBNC ìƒíƒœì˜ ì„¸ê·  ìƒì¡´ ì „ëžµ**ì„ ì—°êµ¬í•˜ëŠ” ì „ë¬¸ê°€ìž…ë‹ˆë‹¤.

**VBNC = Viable But Non-Culturable**

**í•µì‹¬ ê°œë…**:
- ì‚´ì•„ìžˆì§€ë§Œ (Viable) ë°°ì–‘ì€ ì•ˆ ë˜ëŠ” (Non-culturable) ì„¸ê·  ìƒíƒœ
- ìŠ¤íŠ¸ë ˆìŠ¤ í™˜ê²½ì—ì„œ ì§„ìž… (ì €ì˜¨, ì˜ì–‘ ê²°í•, ì‚´ê· ì œ ë“±)
- ì¡°ê±´ ê°œì„  ì‹œ resuscitation (ë˜ì‚´ì•„ë‚¨) ê°€ëŠ¥

**ìµœì‹  ì—°êµ¬ ë™í–¥ (2024-2025)**:
- **AMRê³¼ VBNC**: VBNC ì„¸ê· ì´ í•­ìƒì œ ë‚´ì„± ìœ ì§€/ì¦ê°€
- **í™˜ê²½ persistence**: ìˆ˜ì²˜ë¦¬ ì‹œì„¤, ì‹ìˆ˜ì—ì„œ VBNC ë³‘ì›ì²´ ê²€ì¶œ
- **ê²€ì¶œ ë°©ë²•**: Culture-independent methods í•„ìš”ì„±

#### ì˜ˆìƒ ë°œí‘œ ë‚´ìš©

**1. VBNC Stateì˜ ë°œê²¬ê³¼ ì¤‘ìš”ì„±**

**ì—­ì‚¬**:
- 1982ë…„ Rita Colwell: *Vibrio cholerae*ì—ì„œ ìµœì´ˆ ë°œê²¬
- ì°¨ê°€ìš´ í•´ìˆ˜ì—ì„œ ë°°ì–‘ ë¶ˆê°€ëŠ¥í•˜ì§€ë§Œ ì‚´ì•„ìžˆìŒ
- ì˜¨ë„ ìƒìŠ¹ ì‹œ ë‹¤ì‹œ ë°°ì–‘ ê°€ëŠ¥

**ì¤‘ìš”ì„±**:
```yaml
ê³µì¤‘ë³´ê±´:
  - ë³‘ì›ì²´ê°€ ë°°ì–‘ ì•ˆ ë¼ë„ ê°ì—¼ ê°€ëŠ¥
  - ê¸°ì¡´ ê²€ì¶œë²•(culture) ë¬´ìš©ì§€ë¬¼
  - ìˆ˜ì§ˆ ì•ˆì „ì„± ê³¼ì†Œí‰ê°€

í™˜ê²½ ë¯¸ìƒë¬¼í•™:
  - "Great Plate Count Anomaly" ì„¤ëª…
  - í™˜ê²½ ì„¸ê· ì˜ 99%ê°€ ë°°ì–‘ ë¶ˆê°€ëŠ¥
  - VBNCëŠ” í•˜ë‚˜ì˜ ì„¤ëª…

ê°ì—¼ë³‘í•™:
  - ìž¬ë°œì„± ê°ì—¼ ì›ì¸
  - ë³‘ì› í™˜ê²½ persistent infection
  - í•­ìƒì œ ì¹˜ë£Œ ì‹¤íŒ¨
```

**2. VBNC Induction (ì§„ìž… ì¡°ê±´)**

**ì£¼ìš” ìœ ë„ ìš”ì¸**:
| Stressor | Example | Mechanism |
|----------|---------|-----------|
| **ì˜¨ë„** | 4-10Â°C (cold) | Metabolic slowdown |
| **ì˜ì–‘** | Starvation | Energy conservation |
| **í™”í•™ë¬¼ì§ˆ** | Chlorine, H2O2 | Oxidative stress |
| **í•­ìƒì œ** | Sublethal dose | Stress response |
| **ì—¼ë¶„** | High/low salinity | Osmotic stress |
| **UV** | Solar radiation | DNA damage |

**VBNC vs. ë‹¤ë¥¸ ìƒíƒœ**:
| State | Viability | Culturability | Metabolic Activity | Resuscitation |
|-------|-----------|---------------|-------------------|---------------|
| **Culturable** | âœ… | âœ… | High | N/A |
| **VBNC** | âœ… | âŒ | Low | âœ… (ê°€ëŠ¥) |
| **Dormant (spore)** | âœ… | âŒ | Very low | âœ… |
| **Dead** | âŒ | âŒ | None | âŒ |
| **Persister** | âœ… | âœ… (delayed) | Very low | âœ… |

**3. VBNCì˜ ìƒë¦¬í•™ì  íŠ¹ì§•**

**í˜•íƒœ ë³€í™”**:
- **Cell size ê°ì†Œ**: Rod â†’ Coccoid (êµ¬ê·  í˜•íƒœ)
- **Surface area ìµœì†Œí™”**: ì˜ì–‘/ìˆ˜ë¶„ ì†ì‹¤ ê°ì†Œ
- **Membrane composition ë³€í™”**: Fluidity ì¡°ì ˆ

**ëŒ€ì‚¬ ë³€í™”**:
```yaml
Gene expression:
  - Stress response genes â†‘
    - rpoS (sigma factor)
    - dps (DNA protection)
    - uspA (universal stress protein)

  - Metabolic genes â†“
    - Glycolysis, TCA cycle
    - Ribosomal proteins

  - DNA replication â†“â†“
    - Cell division arrest
```

**í•­ìƒì œ ë‚´ì„± ì¦ê°€**:
- **2024ë…„ Nature Scientific Reports ì—°êµ¬**:
  - Chlorine ì²˜ë¦¬ â†’ VBNC *E. coli*
  - í•­ìƒì œ ë‚´ì„± ì¦ê°€ (ampicillin, tetracycline)
  - Efflux pump genes ê³¼ë°œí˜„

**4. VBNC Resuscitation (íšŒë³µ)**

**Resuscitation ì¡°ê±´**:
- **ì˜¨ë„ ìƒìŠ¹**: 4Â°C â†’ 25-37Â°C
- **ì˜ì–‘ ê³µê¸‰**: Rich media
- **QS signals**: Autoinducer ì¶”ê°€
- **Rpf (Resuscitation promoting factor)**: *Micrococcus* Rpf

**ë©”ì»¤ë‹ˆì¦˜** (ì¶”ì •):
```
Stress removal
  â†“
Sensor kinases activation
  â†“
Transcription factors (rpoS, etc.)
  â†“
Metabolic reactivation
  â†“
Protein synthesis â†‘
  â†“
DNA replication restart
  â†“
Cell division
```

**ëª¨ë“  VBNCê°€ resuscitateí•˜ì§€ëŠ” ì•ŠìŒ**:
- ì¼ë¶€ëŠ” "Point of no return" í†µê³¼ â†’ ì‚¬ë©¸
- Resuscitation rate: 0.001-10% (ì¡°ê±´ ì˜ì¡´)

**5. í™˜ê²½ì—ì„œì˜ VBNC**

**ìˆ˜ì§ˆ ê´€ë¦¬ ë¬¸ì œ**:
- **Drinking water treatment plants**:
  - Ozone, chlorine ì²˜ë¦¬ í›„ VBNC í˜•ì„±
  - 10Â²-10Â³ VBNC cells/100 mL ê²€ì¶œ
  - ë°°ì–‘ë²•ìœ¼ë¡œëŠ” 0 CFU/100 mL (ì•ˆì „ ì˜¤íŒ)

**ë³‘ì› í™˜ê²½**:
- *Acinetobacter baumannii* VBNC (2024 mBio)
- ì†Œë…ì œ ë‚´ì„±, biofilm í˜•ì„±
- ìž¬ë°œì„± ë³‘ì› ê°ì—¼ ì›ì¸

**ì‹í’ˆ ì•ˆì „**:
- *Vibrio*, *Listeria*, *Campylobacter* VBNC
- ëƒ‰ìž¥ ë³´ê´€ ì¤‘ VBNC ì§„ìž…
- ì¡°ë¦¬ ê³¼ì •ì—ì„œ resuscitation â†’ ì‹ì¤‘ë…

#### ì—°êµ¬ì™€ì˜ ì—°ê²°ì 

**ì¼ë°˜ ë¯¸ìƒë¬¼í•™ ì‹¤í—˜ì‹¤ ê´€ì **:

**1. ë°°ì–‘ ë¶ˆê°€ëŠ¥ ì„¸ê·  ì—°êµ¬**:
```yaml
ë¬¸ì œ ì¸ì‹:
  - "Why can't I culture this strain anymore?"
  - ê³„ëŒ€ ë°°ì–‘ ì‹¤íŒ¨ â†’ VBNC ê°€ëŠ¥ì„±

í•´ê²° ì „ëžµ:
  - Resuscitation ì‹œë„
    - Temperature shift
    - Rich media
    - Longer incubation
  - Culture-independent detection
    - qPCR (viability markers)
    - Flow cytometry (LIVE/DEAD staining)
    - Fluorescence in situ hybridization (FISH)
```

**2. í™˜ê²½ ìƒ˜í”Œ ë¶„ì„**:
- **Metagenomicsì˜ í•œê³„**: DNA ê¸°ë°˜ â†’ VBNC í¬í•¨ (viability ë¶ˆëª…)
- **Metatranscriptomics**: RNA ê¸°ë°˜ â†’ Active cells (VBNC êµ¬ë³„ ê°€ëŠ¥?)
- **ë¬¸ì œ**: VBNCë„ low-level transcription ìžˆìŒ â†’ ì—¬ì „ížˆ êµ¬ë³„ ì–´ë ¤ì›€

**3. VBNC ê²€ì¶œ ë°©ë²•**:

**Viability assays**:
| Method | Principle | VBNC Detection |
|--------|-----------|----------------|
| **Plate count** | Culturability | âŒ (VBNC ë†“ì¹¨) |
| **LIVE/DEAD staining** | Membrane integrity | âœ… |
| **DVC (Direct Viable Count)** | Nalidixic acid + nutrients | âœ… |
| **CTC (5-cyano-2,3-ditolyl tetrazolium chloride)** | Respiration | âœ… |
| **qPCR + PMA/EMA** | Viable DNA | âœ… |

**PMA/EMA-qPCR**:
- PMA (Propidium monoazide) ë˜ëŠ” EMA (Ethidium monoazide)
- ì£½ì€ ì„¸ê· ì˜ DNAì™€ ê²°í•© â†’ PCR ì–µì œ
- ì‚´ì•„ìžˆëŠ” ì„¸ê· ë§Œ qPCR ì¦í­ â†’ VBNC í¬í•¨

**4. VBNCì™€ í•­ìƒì œ ë‚´ì„±**:

**AMR ê´€ì **:
```yaml
VBNC ìƒíƒœì˜ AMR íŠ¹ì„±:
  ë‚´ì„± ìœ ì§€:
    - AMR genes ë³´ìœ 
    - Efflux pumps ê³¼ë°œí˜„

  ë‚´ì„± ì¦ê°€:
    - Multidrug efflux (2024 Sci Rep)
    - Metal tolerance

  Resuscitation í›„:
    - AMR ìœ ì§€
    - AMR plasmid ë³´ìœ 
    - ë‹¤ë¥¸ ì„¸ê· ì— HGT ê°€ëŠ¥
```

**í™˜ê²½ AMR reservoir**:
- VBNC ë³‘ì›ì²´ê°€ í™˜ê²½ì— ìž¥ê¸° persistence
- í•­ìƒì œ ë‚´ì„± ìœ ì „ìž ì €ìž¥ì†Œ
- Resuscitation ì‹œ í™•ì‚° ìœ„í—˜

**5. ì‹¤í—˜ ì „ëžµ**:

**VBNC ìœ ë„ ì‹¤í—˜**:
```python
# Protocol example
1. Bacterial culture (exponential phase)
2. Wash with PBS
3. Resuspend in sterile water or PBS
4. Incubate at 4Â°C (ë˜ëŠ” ë‹¤ë¥¸ stress)
5. Sample at time points
   - Plate count (culturable)
   - LIVE/DEAD staining (viable)
   - qPCR (total cells)
6. Monitor VBNC entry (Viable but not culturable)
```

**Resuscitation ì‹¤í—˜**:
```python
1. VBNC cells (confirmed by plate count = 0)
2. Transfer to optimal conditions
   - 37Â°C, rich media (LB, TSB)
3. Monitor recovery
   - Plate count (daily)
   - Optical density
   - Metabolic activity (ATP, respiration)
```

#### í•„ìˆ˜ ë°°ê²½ ì§€ì‹

**1. Great Plate Count Anomaly**

**í˜„ìƒ**:
- í˜„ë¯¸ê²½ ê´€ì°°: 10â¶-10â· cells/mL
- Plate count: 10Â²-10â´ CFU/mL
- â†’ 99%+ ì„¸ê· ì´ ë°°ì–‘ ì•ˆ ë¨!

**ì„¤ëª…**:
1. **VBNC state**: Stressë¡œ ë°°ì–‘ ë¶ˆê°€
2. **Fastidious organisms**: ê¹Œë‹¤ë¡œìš´ ì˜ì–‘ ìš”êµ¬
3. **Slow growers**: ë°°ì–‘ ì‹œê°„ ë¶€ì¡±
4. **Uncultured bacteria**: ë°°ì–‘ë²• ìžì²´ê°€ ì—†ìŒ

**2. Persister Cells vs. VBNC**

**ë¹„êµ**:
| Feature | VBNC | Persister |
|---------|------|-----------|
| **Culturability** | âŒ Immediately | âœ… But delayed |
| **Induction** | Environmental stress | Stochastic (random) |
| **Frequency** | Variable (0.01-100%) | Low (0.001-1%) |
| **Antibiotic tolerance** | âœ… High | âœ… High |
| **Resuscitation** | Needs specific conditions | Spontaneous |
| **Morphology** | Often coccoid | No change |

**ê³µí†µì **:
- ë‘˜ ë‹¤ "dormant-like" state
- í•­ìƒì œ ë‚´ì„± ì¦ê°€
- Metabolic activity ê°ì†Œ

**3. Bacterial Stress Responses**

**Ïƒ factors**:
- **Ïƒ70 (RpoD)**: Housekeeping genes (ì •ìƒ ì¡°ê±´)
- **ÏƒS (RpoS)**: Stationary phase, stress response
  - VBNC ì§„ìž… ì‹œ â†‘â†‘
  - Stress protection genes ì „ì‚¬

**Stress proteins**:
- **Dps (DNA-binding protein from starved cells)**:
  - DNA ë³´í˜¸ (oxidative damage ë°©ì§€)
  - VBNCì—ì„œ ê³¼ë°œí˜„
- **UspA (Universal stress protein A)**:
  - ë‹¤ì–‘í•œ stress ëŒ€ì‘
  - ATP binding

**4. Viability Staining**

**LIVE/DEAD BacLight Kit**:
- **SYTO 9** (green): ëª¨ë“  ì„¸ê·  ì—¼ìƒ‰ (membrane-permeable)
- **Propidium iodide** (red): ì£½ì€ ì„¸ê· ë§Œ (membrane-impermeable)
- **ê²°ê³¼**:
  - Green only: Live
  - Red (or yellow): Dead

**Flow cytometry**:
- High-throughput (ìˆ˜ì²œ cells/ì´ˆ)
- VBNC vs. Dead êµ¬ë³„ ê°€ëŠ¥
- Multiparameter analysis

**5. Quorum Sensing (QS) and Resuscitation**

**QS signals**:
- **AHL (Acyl-homoserine lactone)**: Gram-negative
- **Autoinducing peptide (AIP)**: Gram-positive

**VBNC resuscitation**:
- ì¼ë¶€ ì—°êµ¬: QS signalsê°€ resuscitation ì´‰ì§„
- Mechanism: Cell density ì¸ì‹ â†’ "Safe to grow"
- ë…¼ëž€ ìžˆìŒ (ìž¬í˜„ì„± ë¬¸ì œ)

#### ì˜ˆìƒ ì§ˆë¬¸ & í† ë¡  í¬ì¸íŠ¸

**ë‹¹ì‹ ì´ ë¬¼ì–´ë³¼ ì§ˆë¬¸**:

1. "**í™˜ê²½ ìƒ˜í”Œì—ì„œ VBNC ì„¸ê· ì˜ ë¹„ìœ¨**ì€ ì–´ëŠ ì •ë„ì¸ê°€ìš”? ë°°ì–‘ë²•ìœ¼ë¡œ ë†“ì¹˜ëŠ” ë³‘ì›ì²´ê°€ ì–¼ë§ˆë‚˜ ë§Žì„ê¹Œìš”?"

2. "**VBNC ìƒíƒœì—ì„œë„ ìˆ˜í‰ ìœ ì „ìž ì „ë‹¬(HGT)**ì´ ê°€ëŠ¥í•œê°€ìš”? AMR plasmidë¥¼ ë‹¤ë¥¸ ì„¸ê· ì— ì „ë‹¬í•  ìˆ˜ ìžˆë‚˜ìš”?"

3. "**ë©”íƒ€ì§€ë…¸ë¯¹ìŠ¤/ë©”íƒ€ì „ì‚¬ì²´ ë¶„ì„**ì—ì„œ VBNC ì„¸ê· ì„ ì–´ë–»ê²Œ êµ¬ë³„í•  ìˆ˜ ìžˆë‚˜ìš”? Marker genesê°€ ìžˆë‚˜ìš”?"

4. "**Resuscitation ì„±ê³µë¥ **ì„ ë†’ì´ëŠ” ë°©ë²•ì€? Rpf (Resuscitation promoting factor) ê°™ì€ ê²ƒì„ ì¼ë°˜ì ìœ¼ë¡œ ì‚¬ìš©í•  ìˆ˜ ìžˆë‚˜ìš”?"

5. "**í•­ìƒì œ ì¹˜ë£Œ ê´€ì **ì—ì„œ, VBNC ì„¸ê· ì„ íƒ€ê²Ÿí•˜ëŠ” ì „ëžµì€? Biofilmì²˜ëŸ¼ íŠ¹ë³„í•œ í•­ìƒì œê°€ í•„ìš”í•œê°€ìš”?"

**í† ë¡  ì˜ˆìƒ**:
- **VBNC vs. Dead**: ì •í™•í•œ êµ¬ë³„ ê¸°ì¤€ì€? Viabilityì˜ ì •ì˜?
- **ìˆ˜ì§ˆ ì•ˆì „ ê¸°ì¤€**: Culture-based CFU ê¸°ì¤€ì„ ë°”ê¿”ì•¼ í•˜ë‚˜?
- **Climate change**: ì˜¨ë„ ë³€í™”ê°€ VBNC dynamicsì— ë¯¸ì¹˜ëŠ” ì˜í–¥?
- **í”„ë¡œë°”ì´ì˜¤í‹±ìŠ¤**: VBNC ìƒíƒœì˜ probiotics íš¨ëŠ¥ì€?

**ë„¤íŠ¸working**:
- ë†’ì€ ìš°ì„ ìˆœìœ„ (í™˜ê²½ ë¯¸ìƒë¬¼, AMR ê´€ì‹¬ìž)
- VBNC ê²€ì¶œë²• ê¸°ìˆ  êµë¥˜
- êµ­ì œ ì—°êµ¬ìž (ì¤‘êµ­) â†’ Email follow-up

---

### ðŸ”¹ ë°œí‘œ 3 (14:20-14:45) â­ **ìµœì‹  ë©”ì»¤ë‹ˆì¦˜!**

**ì—°ì‚¬**: Tao Dong (è‘£éŸ¬)
**ì†Œì†**: SUSTech (Southern University of Science and Technology, China), Department of Biology
**ì œëª©**: Type VI Secretion System assembly via phase separation

#### ìµœê·¼ ì—°êµ¬ ë°°ê²½

Dong êµìˆ˜íŒ€ì€ **2025ë…„ íšê¸°ì ì¸ ë°œê²¬**ì„ í–ˆìŠµë‹ˆë‹¤: **T6SS ì¡°ë¦½ì´ liquid-liquid phase separation (LLPS)ì„ í†µí•´ ì´ë£¨ì–´ì§„ë‹¤!**

**ìµœì‹  ì—°êµ¬ (2025)**:

**1. Cell Reports (2025ë…„ 7ì›”)**:
"Fha initiates the inside-out assembly of the type VI secretion system"

**í•µì‹¬ ë°œê²¬**:
- **Inside-out assembly model**: ê¸°ì¡´ "outside-in" ëª¨ë¸ê³¼ ë°˜ëŒ€!
- **Fha protein**: Cytoplasmic scaffold protein
- **LLPS condensates**: Fhaê°€ phase separationìœ¼ë¡œ condensate í˜•ì„±
- **Selective recruitment**: T6SS ë‹¨ë°±ì§ˆë§Œ ì„ íƒì ìœ¼ë¡œ ëª¨ì§‘

**2. mBio (2025)**:
"TssW-PpkA-Fha axis controls the positioning and initiation of the type VI secretion system in *Acidovorax citrulli*"

**PpkA-TssW-Fha axis**:
- **PpkA**: Inner membrane kinase, Fhaë¥¼ ì¸ì‚°í™”
- **TssW**: Outer membrane anchor, T6SS ìœ„ì¹˜ ê²°ì •
- **Fha**: LLPS condensate í˜•ì„±, T6SS component ëª¨ì§‘

#### ì˜ˆìƒ ë°œí‘œ ë‚´ìš©

**1. Type VI Secretion System (T6SS) ê°œìš”**

**êµ¬ì¡°**:
```
Cytoplasm:
  â”œâ”€ Baseplate (TssE/F/G/K complex)
  â”œâ”€ Tube (Hcp hexamers)
  â”œâ”€ Sheath (TssB/C)
  â”œâ”€ Spike (VgrG trimer + PAAR)
  â””â”€ Effectors (attached to spike)

Membrane:
  â”œâ”€ Inner membrane complex (TssL/M)
  â””â”€ Outer membrane anchor (TssJ, TssW)
```

**ìž‘ë™ ì›ë¦¬**:
```
1. Assembly (ì¡°ë¦½)
   â†“
2. Contraction (ìˆ˜ì¶•)
   â†“ (Sheath contracts, VgrG spike penetrates target)
3. Effector delivery (ë…ì†Œ ì£¼ìž…)
   â†“
4. Disassembly (ë¶„í•´)
   â†“ (ClpV ATPase disassembles sheath)
5. Recycling (ìž¬ì¡°ë¦½)
```

**ê¸°ëŠ¥**:
- **í•­ê· ì„± (Antibacterial)**: ê²½ìŸ ì„¸ê·  ê³µê²©
- **í•­ì§„í•µìƒë¬¼ (Anti-eukaryotic)**: Amoeba, macrophage ê³µê²©
- **Virulence**: ë³‘ì›ì„± (ì¼ë¶€ ë³‘ì›ì²´)

**2. ê¸°ì¡´ Assembly Models**

**Outside-in model** (ì´ì „ ì£¼ë¥˜):
```
1. Outer membrane anchor (TssJ) ë¨¼ì € ìœ„ì¹˜ ì„ ì •
   â†“
2. Inner membrane complex (TssL/M) assembly
   â†“
3. Baseplate (TssE/F/G/K) assembly
   â†“
4. Tube/Sheath polymerization (Hcp/TssB/C)
```

**Rationale**: Membrane complexê°€ "landing pad" ì—­í• 

**3. Dongì˜ Inside-out Model (2025) â­**

**New paradigm**:
```
1. Cytoplasmic Fha LLPS condensate í˜•ì„±
   â†“ (Liquid-liquid phase separation)
2. T6SS components selective recruitment
   â†“ (Baseplate proteins: TssE/F/G/K)
3. Baseplate assembly (cytoplasmì—ì„œ!)
   â†“
4. Membrane complex recruitment
   â†“
5. Outer membrane positioning (TssW)
```

**Key innovation**: **Cytoplasmì—ì„œ assembly ì‹œìž‘!**

**4. Fha Proteinê³¼ LLPS**

**Fha (Forkhead-associated domain protein)**:
- **FHA domain**: Phosphothreonine-binding domain
- **IDR (Intrinsically Disordered Region)**: LLPSì— í•„ìˆ˜!

**LLPS ë©”ì»¤ë‹ˆì¦˜**:
```
Fha monomers (dilute)
  â†“ (PpkA phosphorylation)
Phospho-Fha
  â†“ (Multivalent interactions via IDR)
LLPS condensate (liquid droplet)
  â†“ (T6SS protein recruitment)
Assembly platform
```

**Condensate íŠ¹ì„±**:
- **Liquid-like**: Fusion, dripping, wetting
- **Selective**: T6SS proteins â†‘, irrelevant proteins â†“
- **Molecular sieve**: Size/charge exclusion
- **Dynamic**: Protein exchange (in/out)

**5. PpkA-TssW-Fha Axis**

**PpkA (Polyphosphate kinase A)**:
- **Inner membrane kinase**
- Fha ì¸ì‚°í™” â†’ LLPS ì´‰ì§„
- T6SS activation signal?

**TssW**:
- **Outer membrane lipoprotein**
- T6SS positioning (membrane anchor)
- PpkAì™€ TssWì˜ interaction â†’ ìœ„ì¹˜ ê²°ì •

**Coordination**:
```yaml
Positioning (TssW):
  - Outer membraneì—ì„œ "ì—¬ê¸°" ì‹ í˜¸
  - Inner membrane complex ìœ„ì¹˜ ê²°ì •

Initiation (PpkA):
  - Fha phosphorylation
  - LLPS condensate í˜•ì„±

Assembly (Fha):
  - Baseplate components ëª¨ì§‘
  - Inside-out assembly
```

**6. Experimental Evidence**

**Fha knockout**:
- T6SS assembly ì™„ì „ ì‹¤íŒ¨
- Baseplate í˜•ì„± ì•ˆ ë¨

**Fha-IDR deletion**:
- LLPS ë¶ˆê°€
- T6SS assembly ê°ì†Œ

**Fha condensate visualization**:
- Fluorescence microscopy: Fha-GFP puncta (ì  í˜•íƒœ)
- FRAP (Fluorescence Recovery After Photobleaching): Liquid-like dynamics

**In vitro reconstitution**:
- Purified Fha + PpkA â†’ Condensate í˜•ì„±
- T6SS proteins (TssE/F/G) â†’ Condensateì— partition

**7. Conservation and Implications**

**ë‹¤ë¥¸ ì„¸ê· ì—ì„œë„ ë³´ì¡´**:
- ***Pseudomonas aeruginosa*** Fha homolog: ë™ì¼ ê¸°ëŠ¥
- ë‹¤ë¥¸ T6SS-containing bacteriaì—ì„œë„ Fha ì¡´ìž¬ ê°€ëŠ¥ì„±

**ì˜ë¯¸**:
- **LLPS as a general mechanism**: ì„¸ê· ë„ phase separation ì‚¬ìš©!
- **Spatial organization**: Condensateê°€ "assembly factory"
- **Regulation**: PpkA kinaseë¡œ ì¡°ì ˆ ê°€ëŠ¥

#### ì—°êµ¬ì™€ì˜ ì—°ê²°ì 

**ì¼ë°˜ ì„¸ê· í•™ ì‹¤í—˜ì‹¤ ê´€ì **:

**1. Phase Separation in Bacteria**

**LLPS ê°œë…**:
- **ì›ëž˜**: ì§„í•µì„¸í¬ì˜ membraneless organelles (nucleolus, stress granules)
- **ì„¸ê· ì—ì„œë„!**: ìµœê·¼ ë°œê²¬ ì¦ê°€ ì¤‘

**ì„¸ê·  LLPS ì˜ˆì‹œ**:
| System | Protein | Function |
|--------|---------|----------|
| **T6SS** | Fha | Assembly platform |
| **Biofilm** | FapC | Amyloid fiber formation |
| **RNA metabolism** | RNase E | mRNA degradation |
| **DNA repair** | RecA | Homologous recombination |
| **Carbon storage** | CsoS2 | Carboxysome assembly |

**2. T6SS ì—°êµ¬ ëª¨ë¸**

**T6SSë¥¼ ê°€ì§„ ì„¸ê·  ì˜ˆì‹œ**:
```yaml
ë³‘ì›ì²´:
  - Vibrio cholerae: ì„¸ê·  ê²½ìŸ, amoeba ë°©ì–´
  - Pseudomonas aeruginosa: Chronic infection
  - Acinetobacter baumannii: Nosocomial infection
  - Burkholderia: Plant pathogen

í™˜ê²½ ì„¸ê· :
  - Acidovorax citrulli: Plant pathogen (Dongì˜ ëª¨ë¸)
  - Myxococcus: Predatory bacteria
```

**ì‹¤í—˜ ì‹œìŠ¤í…œ**:
- **Antibacterial activity assay**: Co-culture, CFU reduction
- **Microscopy**: T6SS sheath dynamics (TssB-GFP)
- **Mutant analysis**: Knockoutê° component

**3. Protein-Protein Interaction ì—°êµ¬**

**LLPS ì—°êµ¬ ê¸°ë²•**:
```yaml
In vivo:
  - Fluorescence microscopy: Puncta formation
  - FRAP: Dynamics measurement
  - Photo-activated localization microscopy (PALM)

In vitro:
  - Turbidity assay (OD ì¸¡ì •)
  - DIC microscopy: Droplet visualization
  - Rheology: Material properties

Biochemistry:
  - Co-immunoprecipitation: Binding partners
  - Pull-down assays
  - Crosslinking MS: Interaction mapping
```

**IDR (Intrinsically Disordered Region)**:
- **íŠ¹ì§•**: êµ¬ì¡° ì—†ìŒ, flexible
- **ì˜ˆì¸¡ ë„êµ¬**: PONDR, IUPred
- **ê¸°ëŠ¥**: Multivalent interactions, LLPS

**4. ë¶„ë¹„ ì‹œìŠ¤í…œ ë¹„êµ**

**ì„¸ê·  ë¶„ë¹„ ì‹œìŠ¤í…œ 6ê°€ì§€**:
| Type | Structure | Function | Example |
|------|-----------|----------|---------|
| **T1SS** | ABC transporter | Small molecules | Hemolysin |
| **T2SS** | Pseudopilus | Folded proteins | Cholera toxin |
| **T3SS** | Injectisome | Effector injection | Salmonella |
| **T4SS** | Pilus-like | DNA/protein transfer | Agrobacterium |
| **T5SS** | Autotransporter | Self-transport | Pertactin |
| **T6SS** | Contractile nanomachine | Contact-dependent | **LLPS assembly!** |

**T6SS ë…íŠ¹í•¨**:
- Bacteriophage tail ìœ ì‚¬ êµ¬ì¡°
- Contractile sheath (ìœ ì¼!)
- Contact-dependent killing

**5. ì„¸ê·  ê°„ ê²½ìŸ ì—°êµ¬**

**T6SS-mediated competition**:
```yaml
Experimental setup:
  Attacker: T6SS+ strain
  Target: Sensitive strain
  Co-culture: 1:1 ratio

Measurement:
  - CFU count (ê° strain ì„ ë³„ ë°°ì§€)
  - Competition index: (Output ratio) / (Input ratio)
  - Microscopy: Killing events

Applications:
  - Microbiome dynamics
  - Probiotic vs. Pathogen
  - Industrial strain competition
```

#### í•„ìˆ˜ ë°°ê²½ ì§€ì‹

**1. Liquid-Liquid Phase Separation (LLPS)**

**ë¬¼ë¦¬í•™ì  ì›ë¦¬**:
- **Phase diagram**: ì˜¨ë„, ë†ë„ì— ë”°ë¼ single phase â†” two phases
- **Spinodal decomposition**: ë¹ ë¥¸ ìƒ ë¶„ë¦¬
- **Nucleation and growth**: ëŠë¦° droplet í˜•ì„±

**Driving forces**:
- **Multivalent interactions**: ì—¬ëŸ¬ ê°œì˜ ì•½í•œ ê²°í•©
  - Protein-protein (IDR-IDR)
  - Protein-RNA
  - Electrostatic (+ â†” -)
- **Ï€-Ï€ stacking**: Aromatic residues
- **Hydrophobic interactions**

**2. Intrinsically Disordered Regions (IDRs)**

**íŠ¹ì§•**:
- No fixed 3D structure
- High conformational flexibility
- Enriched in charged/polar residues (low hydrophobicity)

**LLPS-prone sequences**:
- **Low complexity domains (LCDs)**: Repetitive sequences
- **Prion-like domains (PrLDs)**: Q/N-rich
- **RGG boxes**: Arg-Gly-Gly repeats

**Fha IDR ì˜ˆìƒ íŠ¹ì§•**:
- Charged residues (K, R, E, D)
- Phosphorylation sites (S, T)
- Low hydrophobicity

**3. Forkhead-Associated (FHA) Domain**

**êµ¬ì¡°**:
- Î²-sandwich fold
- ~100 amino acids

**ê¸°ëŠ¥**:
- **Phosphothreonine binding**: pThr ì¸ì‹
- Signal transduction
- Protein-protein interaction

**FHA domain in bacteria**:
- DNA damage response
- Cell cycle regulation
- Stress response
- **T6SS assembly** (New!)

**4. Baseplate Assembly**

**Baseplate components**:
- **TssE**: Wedge protein
- **TssF/TssG**: Baseplate hub
- **TssK**: Membrane-interacting protein

**êµ¬ì¡°**:
- Hexameric symmetry
- Phage T4 baseplate homology

**Function**:
- Tube/Sheath polymerization platform
- Spike (VgrG) attachment site
- Membrane complex ì—°ê²°

**5. T6SS Regulation**

**Transcriptional regulation**:
- **Quorum sensing**: Cell density
- **Environmental signals**: Temperature, osmolarity
- **Regulatory proteins**: H-NS, Fur, RpoN

**Post-translational regulation**:
- **Phosphorylation**: PpkA â†’ Fha (Dong's work!)
- **TagQRST system**: ClpV degradation control
- **ClpV ATPase**: Sheath disassembly

**Activity regulation**:
- **Constitutive**: Always on (e.g., V52 strain)
- **Inducible**: Stress-responsive
- **Contact-dependent**: Target cell sensing

#### ì˜ˆìƒ ì§ˆë¬¸ & í† ë¡  í¬ì¸íŠ¸

**ë‹¹ì‹ ì´ ë¬¼ì–´ë³¼ ì§ˆë¬¸** (ìµœìš°ì„ !):

1. "**Fha LLPS condensateì˜ í¬ê¸°ì™€ ìˆ˜ëª…**ì€ ì–´ë–»ê²Œ ë˜ë‚˜ìš”? í•˜ë‚˜ì˜ ì„¸ê·  ì„¸í¬ì— ëª‡ ê°œì˜ condensateê°€ í˜•ì„±ë˜ë‚˜ìš”?"

2. "**PpkA kinaseì˜ upstream signal**ì€ ë¬´ì—‡ì¸ê°€ìš”? ì–´ë–¤ í™˜ê²½ ì‹ í˜¸ê°€ PpkAë¥¼ í™œì„±í™”í•´ì„œ T6SS assemblyë¥¼ triggerí•˜ë‚˜ìš”?"

3. "**ë‹¤ë¥¸ T6SS components (TssL/M, Hcp, TssB/C)ë„ Fha condensateë¡œ recruit**ë˜ë‚˜ìš”? ì•„ë‹ˆë©´ baseplate í˜•ì„± í›„ì— ì¶”ê°€ë˜ë‚˜ìš”?"

4. "**In vitro reconstitution**ì—ì„œ minimal componentsëŠ” ë¬´ì—‡ì¸ê°€ìš”? Fha + PpkA + baseplate proteinsë§Œìœ¼ë¡œ functional T6SS assembly ê°€ëŠ¥í•œê°€ìš”?"

5. "**P. aeruginosa ë“± ë‹¤ë¥¸ ë³‘ì›ì²´ì˜ Fha homolog**ë„ ë™ì¼í•œ ë©”ì»¤ë‹ˆì¦˜ì¸ê°€ìš”? Conservation ì •ë„ëŠ”?"

**í† ë¡  ì˜ˆìƒ**:
- **LLPS as a general assembly mechanism**: ë‹¤ë¥¸ ë¶„ë¹„ ì‹œìŠ¤í…œë„ LLPS ì‚¬ìš©?
- **Phase separation in prokaryotes**: ì„¸ê· ì—ì„œ LLPSì˜ prevalence?
- **Therapeutic targeting**: Fha LLPS ì–µì œ â†’ T6SS ë¶ˆí™œì„±í™” â†’ í•­ìƒì œ ëŒ€ì²´?
- **Evolutionary origin**: T6SSê°€ phage tailì—ì„œ ìœ ëž˜ â†’ LLPSë„ phageì—ì„œ?

**ë„¤íŠ¸ì›Œí‚¹**:
- â­â­â­ **ìµœìš°ì„  ë„¤íŠ¸ì›Œí‚¹ ëŒ€ìƒ!**
- ìµœì‹  ì—°êµ¬ (2025 Cell Reports)
- LLPS ì „ë¬¸ê°€ â†’ ê¸°ìˆ  êµë¥˜
- êµ­ì œ í˜‘ë ¥ ê°€ëŠ¥ì„±

---

### ðŸ”¹ ë°œí‘œ 4 (14:45-15:10)

**ì—°ì‚¬**: Stefan Pukatzki
**ì†Œì†**: CCNY (City College of New York), Department of Biology
**ì œëª©**: *Vibrio cholerae* T6SS and bacterial predation

#### ìµœê·¼ ì—°êµ¬ ë°°ê²½

Pukatzki êµìˆ˜ëŠ” **T6SSì˜ ì„ êµ¬ìž**ìž…ë‹ˆë‹¤. 2006ë…„ *Vibrio cholerae*ì—ì„œ T6SSë¥¼ ì²˜ìŒ ë°œê²¬í–ˆê³ , bacterial predationê³¼ competition ì—°êµ¬ë¥¼ ì£¼ë„í•˜ê³  ìžˆìŠµë‹ˆë‹¤.

**ìµœì‹  ì—°êµ¬ (2022-2024)**:

**1. Life Science Alliance (2023)**:
"Pandemic Vibrio cholerae acquired competitive traits from an environmental Vibrio species"

**í•µì‹¬ ë°œê²¬**:
- Pandemic V. choleraeê°€ environmental Vibrio speciesë¡œë¶€í„° T6SS auxiliary cluster íšë“
- Site-specific recombination "lock" â†’ Pandemic strainì—ì„œ stable integration
- Competitive advantage â†’ Pandemic potential

**2. Nature Communications (2022)**:
"Pandemic Vibrio cholerae shuts down site-specific recombination to retain an interbacterial defense mechanism"

**Aux3 (Auxiliary cluster 3)**:
- T6SS effector-immunity module
- Environmental V. cholerae: Mobile (recombination ê°€ëŠ¥)
- Pandemic V. cholerae: Locked (recombination ì–µì œ) â†’ ê²½ìŸë ¥ ìœ ì§€

#### ì˜ˆìƒ ë°œí‘œ ë‚´ìš©

**1. T6SS Discovery**

**ì—­ì‚¬ì  ë°°ê²½**:
- **2006ë…„ PNAS**: Pukatzkiê°€ *Dictyostelium discoideum* (amoeba) ê°ì—¼ ëª¨ë¸ ì‚¬ìš©
- *V. cholerae* vasK mutant â†’ Amoebaì— ì˜í•´ ì£½ìŒ
- Wild-type â†’ Amoebaë¥¼ ì£½ìž„!
- â†’ **T6SS = Anti-predatory weapon**

**ì´ˆê¸° ë°œê²¬**:
- vas (virulence-associated secretion) genes
- hcp (hemolysin co-regulated protein): T6SS tube
- VgrG (Valine-glycine repeat G): T6SS spike
- IcmF, DotU: Membrane components

**2. Bacterial Predation**

**V. cholerae V52 strain**:
- O37 serogroup (non-pandemic)
- **Constitutively active T6SS** (í•­ìƒ on)
- Highly virulent toward other bacteria

**Killing efficiency**:
```yaml
Competition assay:
  V. cholerae V52 (attacker): 10^6 CFU
  E. coli (target): 10^6 CFU
  Co-culture: 4 hours

Result:
  E. coli: 10^1 CFU (10^5-fold reduction!)
  V. cholerae: 10^7 CFU (growth)
```

**Mechanism**:
```
V. cholerae T6SS firing
  â†“
VgrG spike + effectors penetrate E. coli
  â†“
Effector toxins (nucleases, peptidoglycan hydrolases)
  â†“
E. coli cell death
  â†“
V. cholerae nutrient acquisition (debris í¡ìˆ˜)
```

**3. T6SS Effectors and Immunity**

**Effector-Immunity pairs**:
| Effector | Target | Immunity | Function |
|----------|--------|----------|----------|
| **TseL** | Peptidoglycan | TsiL | Cell wall degradation |
| **VgrG-1** | Actin | - | Actin crosslinking |
| **TseH** | NAD+ | TsiH | NAD+ depletion |
| **VasX** | Membrane | - | Membrane disruption |
| **Nucleases** | DNA/RNA | Cognate immunity | Nucleic acid degradation |

**Immunity genes**:
- Effector ì˜†ì— ìœ„ì¹˜ (operon)
- AttackerëŠ” immunity ë°œí˜„ â†’ ìžê¸° ë…ì†Œ ì¤‘í™”
- Target (immunity ì—†ìŒ) â†’ ì£½ìŒ

**4. Interguild and Intraspecies Competition**

**Interguild** (ë‹¤ë¥¸ ì¢… ê°„):
- V. cholerae â†’ E. coli, Salmonella, Shigella
- Broad-spectrum killing

**Intraspecies** (ê°™ì€ ì¢… ë‚´):
- V. cholerae strainsë¼ë¦¬ ê²½ìŸ
- Effector-immunity diversity
- "Immunity type" â†’ ê°™ì€ type = ì„œë¡œ ì£½ì´ì§€ ëª»í•¨

**Example**:
```
Strain A: Effector-X + Immunity-X
Strain B: Effector-Y + Immunity-Y

A vs. B: Both killed (ì„œë¡œ ë‹¤ë¥¸ effector/immunity)

Strain A: Effector-X + Immunity-X
Strain C: Effector-X + Immunity-X

A vs. C: Both survive (ê°™ì€ immunity)
```

**5. Pandemic V. cholerae Evolution**

**Classical biotype**:
- T6SS mutations ì¶•ì 
- Competitive fitness ê°ì†Œ
- 6th pandemic í›„ ì‚¬ë¼ì§

**El Tor biotype**:
- Functional T6SS ìœ ì§€
- 7th pandemic (í˜„ìž¬ê¹Œì§€ ì§€ì†)
- Aux3 cluster íšë“ â†’ ê²½ìŸë ¥ ì¦ê°€

**Aux3 "locking" mechanism**:
- Environmental V. cholerae: Site-specific recombinase í™œì„± â†’ Aux3 mobile
- Pandemic V. cholerae: Recombinase ë¶ˆí™œì„±í™” â†’ Aux3 locked
- â†’ ê²½ìŸë ¥ ìœ ì§€, pandemic potential

**6. Ecological Implications**

**í™˜ê²½ì—ì„œì˜ ì—­í• **:
```yaml
Aquatic environment:
  - Chitinous surfaces (zooplankton, crustaceans)
  - Biofilm formation
  - Interspecies competition

Host:
  - Intestinal colonization
  - Microbiome displacement
  - Immune evasion (macrophage killing)
```

**Microbiome impact**:
- V. cholerae T6SS â†’ ìž¥ë‚´ ë¯¸ìƒë¬¼ ì œê±°
- *Aeromonas veronii* (symbiont) â†’ Displaced by V. cholerae
- Mechanism: T6SS-induced intestinal motility ì¦ê°€ â†’ Physical expulsion

#### ì—°êµ¬ì™€ì˜ ì—°ê²°ì 

**ì¼ë°˜ ì„¸ê· í•™ ì‹¤í—˜ì‹¤ ê´€ì **:

**1. ì„¸ê·  ê°„ ê²½ìŸ ì—°êµ¬**

**Competition assays**:
```python
# Basic protocol
1. Grow attacker and target separately (overnight)
2. Mix 1:1 ratio (or varied ratios)
3. Spot on solid media or co-culture in liquid
4. Incubate (4-24h)
5. Enumerate survivors
   - Selective plating (antibiotic markers)
   - Colony morphology
   - Fluorescent markers (GFP/RFP)
6. Calculate competition index
```

**Competition index (CI)**:
```
CI = (Output ratio: Attacker/Target) / (Input ratio: Attacker/Target)

CI > 1: Attacker wins
CI = 1: Neutral
CI < 1: Target wins
```

**2. T6SS Activity Assays**

**Microscopy-based**:
- TssB-sfGFP fusion: Sheath visualization
- Time-lapse microscopy: Firing events
- Quantify: Firing frequency

**Biochemistry-based**:
- Hcp secretion assay: Western blot (culture supernatant)
- VgrG secretion
- T6SS+ vs. T6SSâˆ’ mutant

**3. Effector-Immunity Discovery**

**Bioinformatics**:
```yaml
Pipeline:
  1. Identify T6SS gene clusters
  2. Search for orphan ORFs (between T6SS genes)
  3. Predict toxin domains (PFAM, HHpred)
  4. Identify downstream immunity genes
  5. Validate experimentally
```

**Experimental validation**:
- Heterologous expression: Effector â†’ E. coli (toxic?)
- Co-expression: Effector + Immunity â†’ E. coli (rescue?)
- Competition assay: Immunity deletion â†’ Self-killing?

**4. Microbiome ì—°êµ¬ ì—°ê²°**

**ìž¥ë‚´ ë¯¸ìƒë¬¼ ê²½ìŸ**:
```yaml
Questions:
  - Which gut bacteria have T6SS?
  - Do probiotics use T6SS to compete with pathogens?
  - Can we engineer probiotics with T6SS?

Applications:
  - Probiotic strain optimization
  - Pathogen exclusion strategies
  - Microbiome engineering
```

**ë©”íƒ€ì§€ë…¸ë¯¹ìŠ¤ì—ì„œ T6SS ê²€ì¶œ**:
- T6SS core genes (hcp, vgrG, clpV, tssM)
- Effector diversity
- Immunity gene distribution

**5. ì§„í™” ì—°êµ¬**

**Horizontal gene transfer (HGT)**:
- T6SS gene clusters often on genomic islands
- Aux clusters: Mobile genetic elements
- Effector-immunity cassettes: HGT hotspots

**Comparative genomics**:
```yaml
Approach:
  1. Collect Vibrio genomes (100s-1000s)
  2. Identify T6SS loci
  3. Compare effector repertoires
  4. Phylogenetic analysis
  5. Recombination detection

Findings (Pukatzki's work):
  - Aux3 acquired from environmental Vibrio
  - Site-specific recombination locked in pandemic
```

#### í•„ìˆ˜ ë°°ê²½ ì§€ì‹

**1. Dictyostelium discoideum**

**íŠ¹ì§•**:
- Social amoeba (ì ê· ë¥˜)
- Model organism (ìœ ì „í•™ ë„êµ¬ í’ë¶€)
- Bacterial predator

**Pukatzkiê°€ ì‚¬ìš©í•œ ì´ìœ **:
- Phagocytosisë¡œ ì„¸ê·  ì„­ì·¨
- V. cholerae vasK mutant â†’ Digested
- Wild-type V. cholerae â†’ Kills amoeba (T6SSë¡œ)
- â†’ T6SSì˜ anti-predatory ê¸°ëŠ¥ ë°œê²¬

**2. Bacteriophage Tail Homology**

**T6SS vs. Phage tail**:
| Component | T6SS | Phage T4 tail |
|-----------|------|---------------|
| **Baseplate** | TssE/F/G/K | gp6/7/10/25 |
| **Tube** | Hcp | gp19 |
| **Sheath** | TssB/TssC | gp18 |
| **Spike** | VgrG | gp5/gp27 |

**Evolutionary origin**:
- T6SS = "Inverted phage tail"
- Phage â†’ ë°”ê¹¥ìœ¼ë¡œ (host ê°ì—¼)
- T6SS â†’ ì˜†ìœ¼ë¡œ (neighbor ê³µê²©)

**3. Contact-Dependent Killing**

**ë©”ì»¤ë‹ˆì¦˜**:
```
Attackerì™€ Targetì´ ì ‘ì´‰í•´ì•¼ í•¨
  â†“
T6SS sheath contraction
  â†“
VgrG spike penetrates target membrane
  â†“
Effectors ì „ë‹¬ (ìˆ˜ì‹­-ìˆ˜ë°± molecules)
  â†“
Target cell death (ì´ˆ-ë¶„ ë‚´)
```

**vs. Secreted toxins**:
- Secreted toxins: Diffusible, ë©€ë¦¬ í¼ì§
- T6SS: Contact-dependent, ì •í™•í•œ íƒ€ê²Ÿ

**4. Auxiliary (Aux) Clusters**

**ì •ì˜**:
- T6SS core genes ì™¸ë¶€ì˜ effector-immunity modules
- Genomic islands ë˜ëŠ” mobile elements

**ê¸°ëŠ¥**:
- ì¶”ê°€ effectors ì œê³µ
- Killing spectrum í™•ìž¥
- Competitive advantage

**Aux3 (Pukatzki's research)**:
- TseV (effector): Vibriocidal activity
- TsiV (immunity): Self-protection
- Site-specific recombination site (attL/attR)
- Pandemic V. cholerae: Recombinase ì–µì œ â†’ Locked

**5. Pandemic vs. Environmental Vibrio**

**Pandemic V. cholerae**:
- O1 or O139 serogroup
- Cholera toxin (ctxAB)
- Toxin-coregulated pilus (TCP)
- El Tor biotype (í˜„ìž¬ pandemic)

**Environmental V. cholerae**:
- Non-O1/non-O139
- No cholera toxin (ëŒ€ë¶€ë¶„)
- Diverse ecological niches
- **More diverse T6SS effectors** (Pukatzki ë°œê²¬)

**Gene flow**:
- Environmental â†’ Pandemic: Aux clusters
- Pandemic â†’ Environmental: Rare

#### ì˜ˆìƒ ì§ˆë¬¸ & í† ë¡  í¬ì¸íŠ¸

**ë‹¹ì‹ ì´ ë¬¼ì–´ë³¼ ì§ˆë¬¸**:

1. "**E. coliì˜ 100,000-fold reduction**ì€ ì–´ë–¤ ì‹¤í—˜ ì¡°ê±´ì—ì„œ ê´€ì°°ë˜ë‚˜ìš”? Time, cell ratio, medium?"

2. "**Intraspecies competition**ì—ì„œ effector-immunity diversityëŠ” ì–¼ë§ˆë‚˜ ë˜ë‚˜ìš”? V. cholerae ì•ˆì—ì„œ ëª‡ ê°€ì§€ immunity typesê°€ ìžˆë‚˜ìš”?"

3. "**ìž¥ë‚´ ë¯¸ìƒë¬¼ ê²½ìŸ**ì—ì„œ T6SSì˜ ì—­í• ì€? Probiotic bacteriaë„ T6SSë¥¼ ê°€ì§€ê³  ìžˆë‚˜ìš”? ë³‘ì›ì²´ ì œê±°ì— ì‚¬ìš© ê°€ëŠ¥í•œê°€ìš”?"

4. "**Aux3 locking mechanism**ì˜ evolutionary benefitì€ ì •í™•ížˆ ë¬´ì—‡ì¸ê°€ìš”? Mobile Aux3 vs. Locked Aux3ì˜ fitness trade-off?"

5. "**T6SS inhibitors** ê°œë°œ ê°€ëŠ¥ì„±ì€? Anti-virulence therapyë¡œì¨?"

**í† ë¡  ì˜ˆìƒ**:
- **Microbiome engineering**: T6SSë¡œ ì›í•˜ëŠ” ê· ì£¼ ì œê±° ê°€ëŠ¥?
- **Phage therapy vs. T6SS therapy**: ì„¸ê· -killing bacteria ì‚¬ìš©?
- **Evolutionary arms race**: Effector-immunity diversityì˜ ê³„ì† ì¦ê°€?
- **Climate change**: í•´ìˆ˜ ì˜¨ë„ ìƒìŠ¹ â†’ V. cholerae T6SS activity ë³€í™”?

**ë„¤íŠ¸ì›Œí‚¹**:
- â­â­â­ **ë†’ì€ ìš°ì„ ìˆœìœ„!**
- T6SS ì„ êµ¬ìž, í’ë¶€í•œ ê²½í—˜
- Bacterial competition ì „ë¬¸ê°€
- ë¯¸êµ­ ë™ë¶€ (ë‰´ìš•) â†’ êµ­ì œ í˜‘ë ¥

---

## ðŸ§  ì„¸ì…˜ ì „ì²´ í•µì‹¬ ìš”ì•½

### S1ì˜ í•µì‹¬ ë©”ì‹œì§€

**"ì„¸ê· ì€ ë‹¤ì–‘í•œ ë©”ì»¤ë‹ˆì¦˜ìœ¼ë¡œ ìƒì¡´í•˜ê³  ê³µê²©í•œë‹¤"**

| ë°œí‘œ | ì£¼ì œ | í•µì‹¬ ë©”ì»¤ë‹ˆì¦˜ | ì—°êµ¬ ì˜ì˜ |
|------|------|--------------|----------|
| **Kim** | MARTX toxin | Pore-forming + Effector delivery | ë…ì†Œ ë‹¤ê¸°ëŠ¥ì„± |
| **Xu** | VBNC state | Dormancy + Resuscitation | ì„¸ê·  persistence |
| **Dong** | T6SS assembly | **LLPS** + Inside-out model | Phase separation |
| **Pukatzki** | T6SS predation | Contact-dependent killing | ì„¸ê·  ê°„ ê²½ìŸ |

### í†µí•©ì  ê´€ì 

**ì„¸ê·  ë³‘ì›ì„±ì˜ ë‹¤ì¸µ êµ¬ì¡°**:
```yaml
Level 1 - ë…ì†Œ (Kim):
  - MARTX: ìˆ™ì£¼ ì„¸í¬ ì§ì ‘ ê³µê²©
  - N-glycan binding
  - Multiple effector domains

Level 2 - ìƒì¡´ ì „ëžµ (Xu):
  - VBNC: ë¶ˆë¦¬í•œ í™˜ê²½ì—ì„œ persistence
  - Resuscitation: ì¡°ê±´ ê°œì„  ì‹œ ìž¬í™œì„±í™”
  - AMR ìœ ì§€

Level 3 - ì„¸í¬ ì¡°ì§í™” (Dong):
  - LLPS: T6SS assembly platform
  - Spatial organization
  - Regulated assembly

Level 4 - ìƒíƒœ ê²½ìŸ (Pukatzki):
  - T6SS: ì„¸ê·  ê°„ ì „ìŸ ë¬´ê¸°
  - Effector-immunity arms race
  - Microbiome dynamics
```

### ì„¸ê· í•™ ì—°êµ¬ì— ì£¼ëŠ” ì‹œì‚¬ì 

**1. ë‹¤í•™ì œì  ì ‘ê·¼ í•„ìš”**:
- êµ¬ì¡°ìƒë¬¼í•™ (MARTX structure, T6SS architecture)
- ì„¸í¬ìƒë¬¼í•™ (LLPS, VBNC physiology)
- ìƒíƒœí•™ (Competition, microbiome)
- ì§„í™”í•™ (HGT, effector diversity)

**2. ìµœì‹  ê¸°ë²• í™œìš©**:
- Phase separation ì—°êµ¬ (FRAP, turbidity assay)
- Single-cell analysis (VBNC heterogeneity)
- Structural biology (Cryo-EM, X-ray)
- Metagenomics (Effector discovery)

**3. ì‘ìš© ê°€ëŠ¥ì„±**:
- ì‹ ê·œ í•­ìƒì œ íƒ€ê²Ÿ (MARTX CPD, T6SS assembly)
- Microbiome engineering (T6SS-based competition)
- ì§„ë‹¨ (VBNC detection)
- Probiotics (T6SS-armed beneficial bacteria)

---

## ðŸ“š ì‚¬ì „ ì½ê¸° (ìš°ì„ ìˆœìœ„)

### í•„ìˆ˜ (Must Read!)

1. **Tao Dong (2025)** - "Fha initiates the inside-out assembly of the type VI secretion system" (Cell Reports)
   - ìµœì‹  LLPS ë©”ì»¤ë‹ˆì¦˜!

2. **Stefan Pukatzki (2023)** - "Pandemic Vibrio cholerae acquired competitive traits from an environmental Vibrio species" (Life Science Alliance)
   - Aux3 cluster evolution

3. **VBNC Review (2024)** - "The VBNC state: a fundamental survival strategy of Acinetobacter baumannii" (mBio)
   - VBNCì™€ AMR ì—°ê²°

### ì¶”ì²œ

4. **MARTX Review (2018)** - "The Modes of Action of MARTX Toxin Effector Domains" (Toxins, Byoung Sik Kim)

5. **LLPS in bacteria (2021)** - "Membraneless organelles formed by liquid-liquid phase separation increase bacterial fitness" (Science Advances)

6. **T6SS Review (2019)** - "Structure and Activity of the Type VI Secretion System" (Microbiology Spectrum)

### ë°°ê²½ ì§€ì‹

7. **Pore-forming toxins** - General review (ì¶”ì²œ: Nature Reviews Microbiology)

8. **Phase separation** - Biological phase separation overview (Cell, 2017)

---

## ðŸŽ¤ ì§ˆë¬¸ ë¦¬ìŠ¤íŠ¸ (Top Priority)

### Must Ask!

1. **[Dong]** "Fha LLPS condensateì˜ in vivo íŠ¹ì„± (í¬ê¸°, ìˆ˜ëª…, ê°œìˆ˜)ê³¼ PpkAì˜ upstream regulationì€ ë¬´ì—‡ì¸ê°€ìš”?"

2. **[Pukatzki]** "E. coli 100,000-fold reductionì˜ ì‹¤í—˜ ì¡°ê±´ê³¼, ìž¥ë‚´ ë¯¸ìƒë¬¼ ê²½ìŸì—ì„œ T6SSì˜ ì—­í• ì€?"

3. **[Xu]** "VBNC ì„¸ê· ì„ ë©”íƒ€ì§€ë…¸ë¯¹ìŠ¤/ë©”íƒ€ì „ì‚¬ì²´ì—ì„œ êµ¬ë³„í•˜ëŠ” ë°©ë²•ê³¼ VBNC ìƒíƒœì—ì„œì˜ HGT ê°€ëŠ¥ì„±ì€?"

### Backup

4. **[Kim]** "N-glycan ê²°í•© íŠ¹ì´ì„±ê³¼ MARTX effector compositionì˜ ë³‘ì›ì„± ì˜í–¥ì€?"

5. **[All]** "ë„¤ ê°€ì§€ ë©”ì»¤ë‹ˆì¦˜ì˜ í†µí•©: VBNC ì„¸ê· ì´ T6SSë¥¼ ê°€ì§€ê³  ìžˆë‚˜ìš”? LLPSê°€ MARTX assemblyì—ë„ ê´€ì—¬í•˜ë‚˜ìš”?"

---

## ðŸ¤ ë„¤íŠ¸ì›Œí‚¹ ìš°ì„ ìˆœìœ„

### 1ìœ„: Tao Dong (SUSTech) â­â­â­

**Why**: 2025 Cell Reports, LLPS ìµœì‹  ì—°êµ¬

**Strategy**:
- ë°œí‘œ ì§í›„ ì§ˆë¬¸ (LLPS mechanism)
- Phase separation ê¸°ë²• êµë¥˜
- Email follow-up: Collaboration ì œì•ˆ

### 2ìœ„: Stefan Pukatzki (CCNY) â­â­â­

**Why**: T6SS pioneer, Bacterial competition expert

**Strategy**:
- Microbiome competition í† ë¡ 
- T6SS effector discovery ë°©ë²•ë¡ 
- êµ­ì œ í˜‘ë ¥ ê°€ëŠ¥ì„±

### 3ìœ„: Zhenbo Xu (South China Univ) â­â­

**Why**: VBNC + AMR ì „ë¬¸ê°€

**Strategy**:
- VBNC detection methods
- Environmental persistence
- ì¤‘êµ­ ì—°êµ¬ìž ë„¤íŠ¸ì›Œí¬

### 4ìœ„: Byoung Sik Kim (Sogang) â­â­

**Why**: êµ­ë‚´ ì—°êµ¬ìž, Vibrio toxin

**Strategy**:
- êµ­ë‚´ í˜‘ë ¥ ìš©ì´
- Toxin mechanism
- Lab visit ê°€ëŠ¥

---

## âš¡ ì„¸ì…˜ ë‹¹ì¼ ì²´í¬ë¦¬ìŠ¤íŠ¸

### ì‚¬ì „ (ì „ë‚ )

- [ ] Dong (2025 Cell Reports) í•„ë…
- [ ] Pukatzki (2023 LSA) ì½ê¸°
- [ ] VBNC, LLPS ê°œë… ì •ë¦¬
- [ ] ì§ˆë¬¸ ë¦¬ìŠ¤íŠ¸ final check

### ë‹¹ì¼ (10/26 ì˜¤í›„)

- [ ] 1ì‹œ ë„ì°© (ì„¸ì…˜ ì‹œìž‘ 30ë¶„ ì „)
- [ ] ì•žìžë¦¬ ì„ ì  (ì§ˆë¬¸í•˜ê¸° ì¢‹ì€ ìœ„ì¹˜)
- [ ] ëª…í•¨ 15ìž¥ ì¤€ë¹„ (4ëª… ì—°ì‚¬ + Î±)
- [ ] ë…¸íŠ¸ë¶/íƒœë¸”ë¦¿ (ë©”ëª¨, ë¬¸í—Œ ì°¸ì¡°)

### ì„¸ì…˜ ì¤‘

- [ ] ê° ë°œí‘œ í•µì‹¬ í¬ì¸íŠ¸ ë©”ëª¨
  - Kim: N-glycan binding mechanism
  - Xu: VBNC detection methods
  - Dong: LLPS condensate properties
  - Pukatzki: Competition assay details
- [ ] Slide ì‚¬ì§„ (í—ˆìš© ì‹œ)
- [ ] íŠ¹ížˆ Dong, Pukatzki ë°œí‘œ ì§‘ì¤‘

### ì§í›„ (15:10-16:00)

- [ ] Dong, Pukatzkiì™€ ì§ì ‘ ëŒ€í™” (ìš°ì„ ìˆœìœ„!)
- [ ] ëª…í•¨ êµí™˜ + ë’·ë©´ ë©”ëª¨
  - ë‚ ì§œ, í•µì‹¬ í† ë¡  ë‚´ìš©
  - Follow-up action items
- [ ] ë‹¤ë¥¸ ì°¸ì„ìžì™€ ë„¤íŠ¸ì›Œí‚¹
- [ ] Coffee break í™œìš©

### ë‹¹ì¼ ì €ë…

- [ ] ë©”ëª¨ ì •ë¦¬ ë° ë””ì§€í„¸í™”
- [ ] ì£¼ìš” ë°œê²¬ ìš”ì•½ (ëž© ê³µìœ ìš©)
- [ ] ë‚´ì¼ ì„¸ì…˜ (Day 2) ì¤€ë¹„

---

## ðŸ“Š ì˜ˆìƒ í•™ìŠµ ì„±ê³¼

### ì§€ì‹ ìŠµë“
âœ… **MARTX toxin**: Effector delivery platformì˜ ëŒ€í‘œ ëª¨ë¸
âœ… **VBNC state**: ì„¸ê·  persistence ì „ëžµê³¼ AMR ì—°ê²°
âœ… **LLPS in bacteria**: ì„¸ê· ë„ phase separation ì‚¬ìš©!
âœ… **T6SS**: ì„¸ê·  ê°„ ê²½ìŸì˜ molecular weapon

### ê¸°ìˆ  ìŠµë“
âœ… **LLPS ì—°êµ¬ ê¸°ë²•**: FRAP, turbidity assay, droplet microscopy
âœ… **VBNC ê²€ì¶œë²•**: LIVE/DEAD, PMA-qPCR, DVC
âœ… **Competition assay**: T6SS-mediated killing ì¸¡ì •
âœ… **Effector-immunity analysis**: Bioinformatics + experimental validation

### ë„¤íŠ¸ì›Œí‚¹
âœ… **êµ­ì œ ì—°êµ¬ìž**: Dong (ì¤‘êµ­), Pukatzki (ë¯¸êµ­), Xu (ì¤‘êµ­)
âœ… **êµ­ë‚´ ì—°êµ¬ìž**: Kim (ì„œê°•ëŒ€)
âœ… **í˜‘ë ¥ ê¸°íšŒ**: LLPS, T6SS, VBNC ì—°êµ¬
âœ… **Follow-up ê³„íš**: Email 3ì¼ ë‚´ ë°œì†¡

### ì—°êµ¬ ì•„ì´ë””ì–´
âœ… **Phase separation in pathogenesis**: LLPSê°€ ë‹¤ë¥¸ virulence factorsì—ë„?
âœ… **VBNC in environment**: í™˜ê²½ ìƒ˜í”Œì—ì„œ VBNC ì„¸ê·  ë¹„ìœ¨?
âœ… **T6SS in microbiome**: ìž¥ë‚´ ë¯¸ìƒë¬¼ T6SS effector diversity?
âœ… **Integrated approach**: VBNC + T6SS + AMR í†µí•© ì—°êµ¬?

---

**í•µì‹¬ Takeaway**:

"ì„¸ê·  ë³‘ì›ì„±ì€ ë…ì†Œ, ìƒì¡´ ì „ëžµ, ì„¸í¬ ì¡°ì§í™”, ìƒíƒœ ê²½ìŸì˜ **ë‹¤ì¸µì  ì‹œìŠ¤í…œ**ì´ë‹¤. ìµœì‹  ë°œê²¬ (LLPS, VBNC-AMR, Aux3 evolution)ì€ ì„¸ê· í•™ì˜ **íŒ¨ëŸ¬ë‹¤ìž„ ì „í™˜**ì„ ë³´ì—¬ì¤€ë‹¤!"

**ì´ ì„¸ì…˜ í›„ ë‹¹ì‹ ì€**:
- ì„¸ê·  ë³‘ì›ì„±ì˜ 4ê°€ì§€ í•µì‹¬ ë©”ì»¤ë‹ˆì¦˜ ì´í•´ âœ…
- ìµœì‹  ì—°êµ¬ ê¸°ë²• (LLPS, VBNC detection) ìŠµë“ âœ…
- êµ­ì œ ì—°êµ¬ìž ë„¤íŠ¸ì›Œí¬ êµ¬ì¶• âœ…
- ìƒˆë¡œìš´ ì—°êµ¬ ì•„ì´ë””ì–´ ë°œêµ´ âœ…
